COMET: Correlating Outcomes with Biochemical Markers to Estimate Time-progression in IPF

Trial Objective

To determine if there are markers of disease such as proteins or genes (biomarkers) in blood, lung tissue or other body fluids that can be used to predict the course of IPF.

Patient Groups:
135 subjects will be recruited with a goal of following approximately 100 subjects in the longitudinal follow up phase. 


  • Approximately 9 visits over 80 weeks
  • Screening visit to determine eligibility
  • Study visits every 16 weeks up to a maximum of 80 weeks


Completed and Research Published

How to Participate

For more information, contact the study coordinator, Todd Dubois at 303.398.1621 or complete the form below.

Who Can Participate

  • Suspected or confirmed diagnosis of IPF
  • Age 35-80 years
  • Only those with confirmed idiopathic pulmonary fibrosis (IPF) will participate in the longitudinal follow up study.

Trial Location

Main Campus, Denver, CO



Trial Sponsors

National Heart Blood and Lung Institute (NHLBI)

Principle Investigators

  • image description
    Kevin Brown, MD